Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (currently amended) An anticancer agent composition comprising a pharmaceutically effective amount of BL-angiostatin as an active ingredient thereof in combination with a pharmaceutically acceptable carrier.

Claim 2. (currently amended) The anticancer agent composition according claim 1 wherein the BL-angiostatin is derived from a mammal.

Claim 3. (currently amended) The anticancer agent composition according to claim 1 [[or 2]] wherein the BL-angiostatin [[is]] comprises one or more fragments of human plasminogen selected from [[a]] the group consisting of Glu¹-Ser⁴⁴¹, Glu¹-Val⁴⁴⁹, Phe⁷⁵-Ser⁴⁴¹ and Phe⁷⁵-Val⁴⁴⁹ fragments of human plasminogen.

Claim 4. (original) A method for producing the BL-angiostatin according to claim 1 comprising the steps of:

equilibrating an affinity trap reactor, in which bacillolysin MA and lysine are immobilized on agarose gel, with a buffer;

adding serum treated with citric acid;
washing with a buffer containing sodium chloride; and
eluting with 6-aminohexanoic acid; wherein,
the buffer does not contain isopropyl alcohol.

Claim 5. (new) The anticancer composition according to claim 2, wherein the BL-angiostatin comprises one or more fragments of human plasminogen selected from the group consisting of Glu¹-Ser⁴⁴¹, Glu¹-Val⁴⁴⁹, Phe⁷⁵-Ser⁴⁴¹ and Phe⁷⁵-Val⁴⁴⁹.

Claim 6. (new) A method for treating a cancer comprising administering to a mammal a pharmaceutically effective amount of BL-angiostatin.

Claim 7. (new) The method for treating cancer according to claim 6, wherein the mammal is a human.

Claim 8. (new) The method for treating cancer according to claim 7, wherein the cancer is breast cancer.

Claim 9. (new) The method for treating cancer according to claim 7, wherein the cancer is lung cancer.

Claim 10. (new) The method for treating cancer according to claim 7, wherein the cancer is pharynx cancer.

Claim 11. (new) The method for treating cancer according to claim 7, wherein the cancer is stomach cancer.

Claim 12. (new) The method for treating cancer according to claim 7, wherein the cancer is pancreas cancer.

Claim 13. (new) The method for treating cancer according to claim 7, wherein the cancer is liver cancer.

Claim 14. (new) The method for treating cancer according to claim 7, wherein the cancer is colon cancer.

Claim 15. (new) The method for treating cancer according to claim 7, wherein the cancer is uterine cancer.

Claim 16. (new) The method for treating cancer according to claim 7, wherein the cancer is ovarian cancer.

Claim 17. (new) The method for treating cancer according to claim 7, wherein the BL-angiostatin is administered in a dosage of 0.1 mg/kg of body weight/day to 100 mg/kg of body weight/day.

Claim 18. (new) The method for treating cancer according to claim 17, wherein the dosage is 1 mg/kg of body weight/day to 10 mg/kg of body weight/day.

Claim 19. (new) The method for treating cancer according to claim 7, wherein the BL-angiostatin comprises a fragment of human plasminogen which is Glu^1-Ser^{441} .